Crinetics Pharmaceuticals, Inc. (CRNX) News
Filter CRNX News Items
CRNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRNX News Highlights
- CRNX's 30 day story count now stands at 10.
- Over the past 22 days, the trend for CRNX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- RARE, WALD and ARI are the most mentioned tickers in articles about CRNX.
Latest CRNX News From Around the Web
Below are the latest news stories about CRINETICS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRNX as an investment opportunity.
Crinetics (CRNX) Stock Surges 70% in a Month: Here's WhyCrinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment. |
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023Time: 1:00 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the |
Why Crinetics Pharmaceuticals Stock Soared This WeekShares of the rare disease specialist Crinetics Pharmaceuticals (NASDAQ: CRNX) have been on fire this week. Through the first four days of trading, the biotech's stock has already gained a healthy 81.3%, according to data provided by S&P Global Market Intelligence. The currently available therapies for acromegaly consist of injectables that can be both painful and inconvenient, given that they typically have to be administered in a doctor's office. |
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share. All of the shares to be sold in the offering are to be sold by Crinetics. |
Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?Crinetics Pharmaceuticals (CRNX) stock is on the rise Monday after the company announced positive clinical trial results. |
Why Is Tenon Medical (TNON) Stock Down 30% Today?Tenon Medical (TNON) stock is falling on Monday after the surgical implant company announced a proposed public offering for its shares. |
Why Is Versus Systems (VS) Stock Up 17% Today?Versus Systems (VS) stock is rising higher on Monday as the business software company's shares experience heavy trading this morning. |
Why Is Nuwellis (NUWE) Stock Down Today?Nuwellis (NUWE) stock is taking a beating on Monday despite a lack of news or increased trading activity for the medical device company. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! |
Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63%Crinetics said Monday its pill succeeded in a study of people with a growth hormone disorder. The biotech stock skyrocketed. |